ASX:AHZ Admedus (AHZ) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Admedus Stock (ASX:AHZ) Get Admedus alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Admedus Limited, a healthcare company, develops, commercializes, and distributes various medical technologies and devices. It manufactures, distributes, and sells proprietary ADAPT regenerative tissue products; and researches and develops regenerative medicine and immunotherapies. The company offers CardioCel, a bio-scaffold material to repair congenital heart deformities and other heart defects, as well as to reconstruct dysfunctional heart valves and valve leaflets; and CardioCel 3D that enables physicians access to an arch reconstruction solution with non-antigenic response and calcification resistance. It also provides VascuCel, a collagen scaffold used in cardiac repairs and reconstructions; ambIT infusion pumps for the delivery of medications and pain relief; arcomed infusion systems; and Eldor, a specialized fenestrated catheters for the infusion of local anesthetics into surgical sites for post-operative pain management. In addition, the company offers DOSI-FUSER, a portable elastomeric pump; and DOSI-PAIN, a wound catheter for postoperative continuous infusion. The company was formerly known as Allied Healthcare Group Limited and changed its name to Admedus Limited in November 2013. Admedus Limited is based in Toowong, Australia. Read More Receive AHZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Admedus and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AHZ Stock News HeadlinesAMEUF Anteris Technologies LtdApril 16, 2024 | seekingalpha.comAnteris Technologies successfully implants five heart patients with valve technologyNovember 23, 2021 | proactiveinvestors.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.September 20 at 2:00 AM | Brownstone Research (Ad)Anteris Technologies’ heart technology on the pulse at London conferenceNovember 9, 2021 | proactiveinvestors.comAnteris Technologies appoints highly experienced chief medical officerSeptember 7, 2021 | proactiveinvestors.comSee More Headlines AHZ Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Admedus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Admedus investors own include Oncolytics Biotech (ONCY), Biosig Technologies (BSGM) and Actinogen Medical (ACW). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:AHZ CIKN/A Webwww.admedus.com Phone61 7 3152 3200FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares5,910,300Free FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (ASX:AHZ) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Admedus Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Admedus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.